Q2 2026 revenue rose 3.4% year-over-year to $2.74B, driven by rare disease and new immunology products, but net income fell due to higher costs and Apellis integration charges. The Apellis deal added SYFOVRE and EMPAVELI. MS revenue declined amid generic competition. Cash reserves dropped, and risks remain.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.